Leadership Changes at Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering biotechnology company, is thrilled to announce the appointment of Corleen Roche as its new Chief Financial Officer (CFO). This significant step is aimed at enhancing the company's strategic financial leadership as it embarks on its first commercial launch of innovative therapies for cancer. Ms. Roche will officially assume her role on August 6.
Strategic Growth and Experience
Frederick G. Vogt, Ph.D., J.D., Interim CEO of Iovance, expressed his enthusiasm about Ms. Roche's appointment during this crucial time. He highlighted her extensive background in financial leadership and multiple successful product launches as critical assets that will aid in driving revenue growth and managing the company's balance sheet. Ms. Roche brings over 30 years of experience in the biotech and life sciences sectors, with a rich history of executive roles in publicly traded companies.
Notable Achievements
Before joining Iovance, Ms. Roche served as the CFO at CG Oncology, a company dedicated to clinical biopharmaceutical advancements. Her previous roles include key financial leadership positions at Immunome, Biogen, and CSL Behring, where she played vital roles in important product launches. Noteworthy products include ZARXIO, the first FDA-approved biosimilar, and GLATOPA, the first complex generic for multiple sclerosis.
Focus on Patient-Centered Innovation
In her new role, Ms. Roche aims to propel Iovance's growth trajectory while focusing on pipeline investments that tap into the most promising opportunities for cancer therapies. She expressed her commitment to supporting the company’s mission of patient-centered care while ensuring financial stability. The goal is to position Iovance as a forward-thinking company in the biotechnology industry.
The Vision of Iovance Biotherapeutics
Iovance Biotherapeutics is dedicated to being a leader in the development of tumor infiltrating lymphocyte therapies for cancer treatment. Their innovative approach seeks to harness the power of the human immune system, enabling it to recognize and destroy cancerous cells in individual patients. The company’s TIL platform has shown promising clinical results across various solid tumors, reinforcing their commitment to advancing cell therapy.
First FDA-Approved T Cell Therapy
With the recent approval of Amtagvi, Iovance's T cell therapy targeting solid tumors, the company has taken significant strides forward. This therapy represents a pivotal development within the biotechnology landscape and marks a new chapter in the fight against cancer. The team at Iovance strives for continuous innovation, including advancements in gene-edited cell therapy, aiming to improve the quality of life for cancer patients.
Company Contact Information
For inquiries, potential investors, and media relations, Iovance provides accessible contact information.
Investors Contact: IR@iovance.com
Phone: 650-260-7120 ext. 150
Media Contact: PR@iovance.com
Phone: 650-260-7120 ext. 150
Frequently Asked Questions
Who is Corleen Roche?
Corleen Roche is the newly appointed Chief Financial Officer of Iovance Biotherapeutics, bringing extensive experience in biotechnology finance.
What will Corleen Roche focus on in her new role?
She will concentrate on maximizing revenue growth and ensuring financial stability as Iovance launches new therapies.
What are Iovance's main products?
Iovance specializes in tumor infiltrating lymphocyte therapies, with Amtagvi being the first FDA-approved T cell therapy for solid tumors.
How does Iovance's technology work?
Their technology aims to harness the body's immune system to recognize and eliminate cancer cells effectively.
How can investors contact Iovance Biotherapeutics?
Investors can reach out via email at IR@iovance.com or by phone at 650-260-7120 ext. 150.
